Caspofungin for prophylaxis and treatment of fungal infections in adolescents and adults: A meta-analysis of randomized controlled trials

Pharmazie

Volumn 67, Issue 4, 2012, Pages 267-273

  Yuan, Xin ^a,b   Wang, Rui ^a   Bai, Chang Qing ^b   Song, Xiu Jie ^a   Liu, You Ning ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; CANDIDIASIS; CHILL; CLINICAL ASSESSMENT; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; EMBASE; FEVER; HEADACHE; HUMAN; MEDLINE; META ANALYSIS; MICROBIOLOGY; MORTALITY; MYCOSIS; NONHUMAN; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; FOLLOW UP; RECURRENT DISEASE; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; DATA INTERPRETATION, STATISTICAL; ECHINOCANDINS; FOLLOW-UP STUDIES; HUMANS; MYCOSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SURVIVAL; TREATMENT OUTCOME;

EID: 84861723200     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1793     Document Type: Review

References (27)

1. Abruzzo GK, Flattery AM, Gill CJ, Kong L, Smith JG, Pikounis VB, Balkovec JM, Bouffard AF, Dropinski JF, Rosen H, Kropp H, Bartizal K. (1997) Evaluation of the echinocandin antifungal MK-0991(L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 41: 2333-2338.
2. Abruzzo GK, Gill CJ, Flattery AM, Kong L, Leighton C, Smith JG, Pikounis VB, Bartizal K, Rosen H (2000) Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 44: 2310-2318.
3. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA (2002) Randomized, double- blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 46: 451-457.
4. Bal AM (2010) The echinocandins: three useful choices or three too many? Int J Antimicrob Agents 35: 13-18.
5. Bartizal K, Smith JG, Gill CJ, et al. (1997) Preclinical efficacy of MK-0991 in pancytopenic mouse models of disseminated candidiasis and aspergillosis. 37th interscience Conference on Antimicrobial Agents and Chemotherapy. F-80.
6. Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, Pallavicini FB, Viscoli C (2006) Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6: 21.
7. Caillot D, Thiébaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F, Larché J, Monchecourt F, Alfandari S, Mahi L (2007) Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies. Cancer 110: 2740-2746.
8. Colombo AL, Perfect J, DiNubile M, Bartizal K, Motyl M, Hicks P, Lupinacci R, Sable C, Kartsonis N (2003) Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22: 470-474.
9. Falagas ME, Ntziora F, Betsi GI, Samonis G (2007) Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials. Int J Antimicrob Agents 29: 136-143.
10. Gudlaugsson O, Gillespie S, Lee K Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37: 1172-1177.
11. Hiemenz J, Raad I, Boogaerts M, et al. (2001) Efficacy of caspofungin as salvage therapy in invasive aspergillosis compared to standard therapy in a historical cohort. Focus on Fungal Infections II: 022.
12. Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
13. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'brien S, Verstovsek S, Faderl S, Zhou X, Raad II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH (2006) Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 50: 143-147.
14. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347: 2020-2029.
15. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45: 883-893.
16. Pappas PG, Kauffman CA, Andes D, BenjaminDKJr, Calandra TF,Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503-535.
17. Raad II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, Kontoyiannis DP, Hachem RY (2008) Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with highdose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 22: 496-503.
18. Richardson MD (2005) Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 56 (Suppl 1): i5-i11.
19. Singh N, Limaye AP, Forrest G, Safdar N, Muñoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, Del Busto R, Aguado JM, Fisher RA, Klintmalm GB, Miller R, Wagener MM, Lewis RE, Kontoyiannis DP, Husain S (2006) Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81: 320-326.
20. Smith JG, Abruzzo CJ, Flattery AM, et al. (1996) Evaluation of pneumocandin L-743872 in neutropenic mouse models of disseminated candidiasis and aspergillosis. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy F-41.
21. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S, Grillot R (2004) Epidemiology of candidemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23: 317-322.
22. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA (2001) A randomized double-blind Study of caspofungin versus amphotericin for the treatment of candidal oesophagitis. Clin Infect Dis 33: 1529-1535.
23. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, Smietana JM, DiNubile MJ, Sable CA (2002) A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113: 294-299.
24. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351: 1391-1402.
25. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46: 327-360.
26. Wang J, Sun A-N, Wu D-P, et al. (2007) Comparison of caspofungin and liposomal amphotericin B for empirical antifungal therapy in patients with hematologic disease. Zhongguo Kang Sheng Su Za Zhi 32: 316-319.
27. Wenzel RP (1995) Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 20: 1531-1534.